Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Rating of “Buy” from Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has been assigned an average rating of “Buy” from the five research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a strong buy rating to the company.

A number of analysts have recently commented on IKT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, January 22nd. HC Wainwright raised Inhibikase Therapeutics to a “strong-buy” rating in a research report on Friday, December 26th. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, December 1st. Finally, Cantor Fitzgerald upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th.

Inhibikase Therapeutics Price Performance

Inhibikase Therapeutics stock opened at $1.69 on Wednesday. The firm has a 50 day moving average of $1.67. Inhibikase Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.32. The firm has a market capitalization of $127.05 million, a PE ratio of -4.33 and a beta of 0.84.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) EPS for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.